Isomorphic Labs and Novartis Establish Strategic Collaboration for Multi-Target Research

Isomorphic Labs, a digital biology company specializing in advancing drug discovery through artificial intelligence (AI), has revealed a strategic research collaboration with Novartis aimed at identifying small molecule therapeutics for three undisclosed targets.

Demis Hassabis, the CEO and founder of Isomorphic Labs, highlighted the common mission to redefine medicine for improved and extended lives. The collaboration integrates Isomorphic's state-of-the-art AI and technology platform, including the latest AlphaFold model, with Novartis's expertise in creating groundbreaking medicines.

Fiona Marshall, President of Biomedical Research at Novartis, emphasized the transformative potential of advanced AI technologies like AlphaFold in reshaping drug discovery and expediting the development of life-changing medicines. The collaboration aims to leverage the unique strengths of both companies, combining AI and data science with medicinal chemistry and in-depth disease area knowledge for AI-driven drug discovery.

Operating independently within Alphabet, Isomorphic Labs focuses exclusively on applying AI to drug discovery, reimagining the drug discovery process with an AI-first approach to building predictive and generative models of biological phenomena. Isomorphic Labs has made significant progress with the Next Generation of AlphaFold, extending its capabilities to encompass small molecules and nucleic acids.

Under the collaboration agreement, Novartis will provide Isomorphic Labs with an upfront payment of $37.5 million, along with funding for specific research costs. Isomorphic Labs is poised to receive up to $1.2 billion in performance-based milestone payments, excluding the initial payment, and may also receive tiered royalties on net sales ranging from mid-single to low double digits. The collaboration signifies a joint effort to explore new frontiers in AI-driven drug discovery.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!